bluebird bio Inc. (BLUE)’s Financial Results Comparing With Kezar Life Sciences Inc. (NASDAQ:KZR)

bluebird bio Inc. (NASDAQ:BLUE) and Kezar Life Sciences Inc. (NASDAQ:KZR), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
bluebird bio Inc. 39.50M 187.27 523.83M -8.19 0.00
Kezar Life Sciences Inc. N/A 0.00 19.68M -1.05 0.00

Table 1 demonstrates bluebird bio Inc. and Kezar Life Sciences Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows us the net margins, return on equity and return on assets of both companies.

Net Margins Return on Equity Return on Assets
bluebird bio Inc. -1,326.15% -31.5% -26.6%
Kezar Life Sciences Inc. 0.00% 0% 0%


13.1 and 13.1 are the respective Current Ratio and a Quick Ratio of bluebird bio Inc. Its rival Kezar Life Sciences Inc.’s Current and Quick Ratios are 32.9 and 32.9 respectively. Kezar Life Sciences Inc. has a better chance of clearing its pay short and long-term debts than bluebird bio Inc.

Analyst Ratings

Ratings and Recommendations for bluebird bio Inc. and Kezar Life Sciences Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
bluebird bio Inc. 0 2 5 2.71
Kezar Life Sciences Inc. 0 0 0 0.00

The upside potential is 9.29% for bluebird bio Inc. with average target price of $147.83.

Insider & Institutional Ownership

Roughly 0% of bluebird bio Inc. shares are held by institutional investors while 47.5% of Kezar Life Sciences Inc. are owned by institutional investors. 0.3% are bluebird bio Inc.’s share held by insiders. Insiders Comparatively, held 22.8% of Kezar Life Sciences Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
bluebird bio Inc. -16.88% -23.58% -30.98% -43.22% -39.16% -42.64%
Kezar Life Sciences Inc. -9.94% 16.22% 45.19% 0% 0% 50.59%

For the past year bluebird bio Inc. has -42.64% weaker performance while Kezar Life Sciences Inc. has 50.59% stronger performance.


On 7 of the 10 factors Kezar Life Sciences Inc. beats bluebird bio Inc.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.